Genetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD - Full Text View

Sponsored by:	Centre Hospitalier Universitaire Dijon
Information provided by:	Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier:	NCT00629044

Purpose

The aim of this study is to assess the implicitement of the cholesterol 24 S hydroxylase gene and the 24 S hydroxycholesterol in glaucoma and in age related macular degeneration.

Condition	Intervention
Glaucoma	Biological: Assessing the blood level of cholesterol 24 S Hydroxylase Biological: Assessing the blood level of cholesterol 24 S hydroxylase Biological: assessing the blood level of cholesterol 24 S hydroxylase

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Cholesterol Glaucoma

Drug Information available for: Cholest-5-en-3-ol (3beta)-

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Screening, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment
Official Title:	Etude du Polymorphysme génétique de la cholestérol 24S Hydroxylase et Des Teneurs en 24S hydroxycholestérol Chez Des Patients Atteints de Glaucome ou de dégénérescence Maculaire liée à l'âge.

Further study details as provided by Centre Hospitalier Universitaire Dijon:

Primary Outcome Measures:

To know if cholesterol 24 S hydroxylase and 24 hydroxycholesterol are involve in Glaucoma and AMD [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	320
Study Start Date:	November 2007
Estimated Primary Completion Date:	November 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
G: Active Comparator	Biological: Assessing the blood level of cholesterol 24 S Hydroxylase Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
AMD: Active Comparator	Biological: Assessing the blood level of cholesterol 24 S hydroxylase Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
Healthy subjects: Active Comparator	Biological: assessing the blood level of cholesterol 24 S hydroxylase Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects

Eligibility

Ages Eligible for Study:	40 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Patient with Glaucoma
Patient with AMD
Healthy patient

Exclusion Criteria:

All patients who use any treatment in order to maintain in normal value their blood cholesterol

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00629044

Contacts

Contact: Frédéric Nicot, CRA

33 3 80293756

frederic.nicot@chu-dijon.fr

Locations

France, Burgundy
Ophthalmology Unit CHU Dijon	Recruiting
Dijon, Burgundy, France, 21000
Contact: Frédéric Nicot, CRA 33 3 80293756 frederic.nicot@chu-dijon.fr
Principal Investigator: Catherine Creuzot-Garcher, MD, PhD

Sponsors and Collaborators

Centre Hospitalier Universitaire Dijon

Investigators

Principal Investigator:

Catherine Creuzot-Gracher, MD, PhD

CHU Dijon

More Information

Publications:

Joffre C, Souchier M, Grégoire S, Viau S, Bretillon L, Acar N, Bron AM, Creuzot-Garcher C. Differences in meibomian fatty acid composition in patients with meibomian gland dysfunction and aqueous-deficient dry eye. Br J Ophthalmol. 2008 Jan;92(1):116-9.

Responsible Party:	CHU Dijon ( Professor Catherine Creuzot-Garcher )
Study ID Numbers:	PHRC IR 2006
Study First Received:	February 25, 2008
Last Updated:	February 25, 2008
ClinicalTrials.gov Identifier:	NCT00629044
Health Authority:	France: Afssaps - French Health Products Safety Agency

Study placed in the following topic categories:

Glaucoma
Eye Diseases
Hypertension
Ocular Hypertension

ClinicalTrials.gov processed this record on January 16, 2009